2006
DOI: 10.1136/ard.2005.040428
|View full text |Cite
|
Sign up to set email alerts
|

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study

Abstract: Background: Osteonecrosis is common in systemic lupus erythematosus (SLE) and often disabling. The role of glucocorticoids in its development is well known. Objective: To explore other possible risk factors for osteonecrosis in SLE. Methods: A nested matched case-control study undertaken in the context of a large, longitudinal, multiethnic lupus cohort (LUMINA), currently formed of 571 SLE patients meeting American College of Rheumatology criteria. All those developing symptomatic osteonecrosis after the diagn… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
57
2
8

Year Published

2009
2009
2017
2017

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 65 publications
(69 citation statements)
references
References 36 publications
2
57
2
8
Order By: Relevance
“…Potentially confounding factors and multicollinearity were evaluated. Propensity score approaches (D'Agostino, 1998;Calvo-Alen et al, 2006) were used in a secondary analysis to control for strong associations between bisphosphonate exposure and the conditions for which bisphosphonates are prescribed. Covariates included general indicators of health, demographics, co-morbidities, dental diagnoses and procedures, and treatment with medications other than bisphosphonates.…”
Section: Statistical Considerationsmentioning
confidence: 99%
“…Potentially confounding factors and multicollinearity were evaluated. Propensity score approaches (D'Agostino, 1998;Calvo-Alen et al, 2006) were used in a secondary analysis to control for strong associations between bisphosphonate exposure and the conditions for which bisphosphonates are prescribed. Covariates included general indicators of health, demographics, co-morbidities, dental diagnoses and procedures, and treatment with medications other than bisphosphonates.…”
Section: Statistical Considerationsmentioning
confidence: 99%
“…It is also known to occur as one of the serious complications of glucocorticoid treatment of SLE. Among several factors related to ION, glucocorticoid therapy is considered to be one of essential importance [3]. There have been a lot of reports of ION onset in SLE patients to date, but the exact incidence of ION in this group is unknown.…”
Section: Introductionmentioning
confidence: 99%
“…The etiology or pathogenesis of this disorder has not been fully clariied, and no prophylaxis has been established to date. The risk of ION in SLE patients is considered to be due to both the SLE itself and the concomitant use of glucocorticoid because, in occasional cases, ION has been noted in the absence of glucocorticoid therapy [3]. In addition, the risk of developing ION has been linked to numerous factors such as glucocorticoid use, alcohol consumption, cigarete smoking, and several rheumatic diseases including SLE.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations